Sartorius Stedim Biotech S.A. (ETR:56S1)

Germany flag Germany · Delayed Price · Currency is EUR
159.80
-2.60 (-1.60%)
At close: Apr 28, 2026
-20.58%
Market Cap 15.26B
Revenue (ttm) 2.98B
Net Income (ttm) 268.10M
Shares Out n/a
EPS (ttm) 2.76
PE Ratio 56.90
Forward PE 29.41
Dividend 0.69 (0.37%)
Ex-Dividend Date Mar 31, 2026
Volume n/a
Average Volume 80
Open 159.80
Previous Close 162.40
Day's Range 159.80 - 159.80
52-Week Range 159.70 - 223.50
Beta 1.17
RSI 38.09
Earnings Date Apr 23, 2026

About Sartorius Stedim Biotech

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiolog... [Read more]

Sector Healthcare
Founded 1978
Employees 10,456
Stock Exchange Deutsche Börse Xetra
Ticker Symbol 56S1
Full Company Profile

Financial Performance

In 2025, Sartorius Stedim Biotech's revenue was 2.97 billion, an increase of 6.74% compared to the previous year's 2.78 billion. Earnings were 265.60 million, an increase of 51.68%.

News

Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing

AUBAGNE, France--(BUSINESS WIRE)-- #CGT--Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing.

9 months ago - Business Wire

Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa

KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech, a...

9 months ago - GlobeNewsWire

Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform

AUBAGNE, France & BRATISLAVA, Slovakia--(BUSINESS WIRE)--Sartorius Stedim Biotech and Sensible Biotechnologies are scaling up a unique cell-based manufacturing platform for clinical-grade therapeutic ...

10 months ago - Business Wire

Sartorius, Sartorius Stedim Biotech shares jump after results beat

Shares in Sartorius jumped 15.6% on Tuesday after the Franco-German lab supplies maker's preliminary annual results beat expectations and despite a cautious outlook for 2025.

1 year ago - Reuters

10 stocks for investors looking for ‘wonderful companies at a fair price'

As money managers talk about various methods of selecting quality companies, investors might also think about diversification, which can lower risk and broaden opportunities.

2 years ago - Market Watch

Sartorius, Sartorius Stedim shares fall after Polyplus acquisition

Shares in German pharmaceutical and laboratory equipment supplier Sartorius AG and its France-listed subsidiary Sartorius Stedim Biotech SA DIM, -6.51% fell in opening trade on Friday after the compan...

3 years ago - Market Watch